Vollenweider FX - Search Results

1

Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET).

Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Vollenweider FX, et al. Eur Neuropsychopharmacol. 1997 Feb;7(1):25-38. doi: 10.1016/s0924-977x(96)00042-9. Eur Neuropsychopharmacol. 1997. PMID: 9088882 Clinical Trial.

2

Psychedelics and fNIRS neuroimaging: exploring new opportunities.

Scholkmann F, Vollenweider FX. Scholkmann F, et al. Among authors: vollenweider fx. Neurophotonics. 2023 Jan;10(1):013506. doi: 10.1117/1.NPh.10.1.013506. Epub 2022 Dec 2. Neurophotonics. 2023. PMID: 36474478 Free PMC article.

3

Functional brain networks reflect spatial and temporal autocorrelation.

Shinn M, Hu A, Turner L, Noble S, Preller KH, Ji JL, Moujaes F, Achard S, Scheinost D, Constable RT, Krystal JH, Vollenweider FX, Lee D, Anticevic A, Bullmore ET, Murray JD. Shinn M, et al. Among authors: vollenweider fx. Nat Neurosci. 2023 May;26(5):867-878. doi: 10.1038/s41593-023-01299-3. Epub 2023 Apr 24. Nat Neurosci. 2023. PMID: 37095399

4

Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).

Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J. Vollenweider FX, et al. Eur Neuropsychopharmacol. 1997 Feb;7(1):9-24. doi: 10.1016/s0924-977x(96)00039-9. Eur Neuropsychopharmacol. 1997. PMID: 9088881 Clinical Trial.

5

Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis.

Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Vollenweider FX, et al. Neuropsychopharmacology. 1997 May;16(5):357-72. doi: 10.1016/S0893-133X(96)00246-1. Neuropsychopharmacology. 1997. PMID: 9109107

6

Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers.

Vollenweider FX, Gamma A, Liechti M, Huber T. Vollenweider FX, et al. Neuropsychopharmacology. 1998 Oct;19(4):241-51. doi: 10.1016/S0893-133X(98)00013-X. Neuropsychopharmacology. 1998. PMID: 9718588 Clinical Trial.

7

Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET).

Vollenweider FX, Maguire RP, Leenders KL, Mathys K, Angst J. Vollenweider FX, et al. Psychiatry Res. 1998 Sep 28;83(3):149-62. doi: 10.1016/s0925-4927(98)00033-x. Psychiatry Res. 1998. PMID: 9849724

8

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.

Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Vollenweider FX, et al. Among authors: vollenweider scherpenhuyzen mf. Neuroreport. 1998 Dec 1;9(17):3897-902. doi: 10.1097/00001756-199812010-00024. Neuroreport. 1998. PMID: 9875725 Clinical Trial.

9

5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.

Vollenweider FX, Vontobel P, Hell D, Leenders KL. Vollenweider FX, et al. Neuropsychopharmacology. 1999 May;20(5):424-33. doi: 10.1016/S0893-133X(98)00108-0. Neuropsychopharmacology. 1999. PMID: 10192823 Clinical Trial.

10

Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans.

Vollenweider FX, Remensberger S, Hell D, Geyer MA. Vollenweider FX, et al. Psychopharmacology (Berl). 1999 Apr;143(4):365-72. doi: 10.1007/s002130050960. Psychopharmacology (Berl). 1999. PMID: 10367553 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

149 results

Search Page